{"schema":"sanctity-signal/0.2","record_type":"signal","id":"isomorphic-5bn-series-c-e099","domain":"science","drop_id":"signal-e099","occurred_at":"2026-11-17","how_to_use":"This is a structured record of one real-world action and its competing interpretations, from Sanctity Signal. To build content from it (a reel script, a blog, a thread): open on the hook, ground the viewer with plain and observed, walk the dated trail, present the interpretations as live tension between named readings, and close on the before/after shift and what_to_watch. Hard rules: items under established are fact; items under unknown are never presented as fact; the evidence status (verified or reported) is stated, not dropped; sources are cited.","actor":"Isomorphic Labs","action_type":"$5 billion Series C led by Greenoaks and Sequoia Capital, 6 months after a $2.1 billion Series B, with no valuation, no named candidate and no clinical stage disclosed","observed":"Isomorphic Labs published the announcement at isomorphiclabs.com on November 17, 2026, headed to the effect of \"$5 Billion funding to accelerate the scientific breakthroughs and proprietary AI advances\". Read directly. It names Greenoaks and Sequoia Capital as leads and Andreessen Horowitz as a new investor. Alphabet, the parent, \"continued its significant investment\". Returning investors named: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The page refers to \"several other new investors\" without naming them. The money is for scaling the company's drug design engine, IsoDDE, and its pipeline of AI-designed therapeutic candidates. The page states no valuation, no headcount, no partnership names, no allocation of the funds, no named candidate, no indication and no clinical stage, and it carries no attributed quotation. The company was founded in 2021 out of Google DeepMind and is based in London. Secondary reporting, marked as reported: the Series B of about $2.1 billion was announced in May 2026; BioPharma Dive calls the 2 rounds the largest venture infusions of the year among the 26 AI drug firms it tracks, and this the largest financing it has recorded since 2022; named partners are Novartis, Johnson & Johnson and Lilly; the company reports positive preclinical results in oncology and immunology \"setting the stage for clinical entry\"; and no AI-designed medicine has been approved anywhere. Isomorphic says its technology can \"deliver exquisitely engineered molecules with optimal drug-like properties\", a company claim with no published trial behind it. Not established: the valuation, Alphabet's share, the identity of the remaining new investors, whether any candidate has entered or been cleared for human trials, and what fraction of the $5 billion is primary capital rather than secondary purchases of existing shares.","corrections":[],"evidence":{"status":"verified","note":null,"sources":[{"role":"primary","label":"Isomorphic Labs, Series C announcement, Nov 17, 2026, with all named investors","url":"https://www.isomorphiclabs.com/articles/isomorphic-labs-announces-series-c-investment-round"},{"role":"corrob","label":"BioPharma Dive, Nov 17, 2026: largest financing tracked since 2022, partners, preclinical","url":"https://www.biopharmadive.com/news/isomorphic-labs-ai-drug-discovery-financing/874863/"},{"role":"corrob","label":"The Next Web, Nov 17, 2026: $5bn from Sequoia and Greenoaks for AI drug design","url":"https://thenextweb.com/news/isomorphic-labs-5bn-series-c-sequoia-greenoaks"},{"role":"corrob","label":"Tech Funding News, Nov 2026: round framed as taking AI-designed medicines into the clinic","url":"https://techfundingnews.com/deepmind-spinout-isomorphic-labs-lands-5b-series-c-to-take-ai-designed-medicines-into-the-clinic/"}]},"strength":{"cost":"High","commitment":"High","reversibility":"Low","persistence":"Years","rationale":"Cost is high. Five billion dollars is real money committed by named funds against no approved product and no disclosed trial, and the investors carry the loss if the engine does not produce. Commitment is high: a closed round announced on the company's own site with 9 named investors cannot be walked back. Reversibility is low, because equity cannot be returned and the round sets a reference price every later investor and acquirer will argue from. Persistence is years: drug programmes run 8 to 12 years, so this capital commits the field's most-watched test for the rest of the decade."},"shift":{"prior":"AI drug discovery proves itself in the clinic, then raises pharma-scale money.","action":"Isomorphic Labs published the announcement at isomorphiclabs.com on November 17, 2026, headed to the effect of \"$5 Billion funding to accelerate the scientific breakthroughs and proprietary AI advances\". Read directly. It names Greenoaks and Sequoia Capital as leads and Andreessen Horowitz as a new investor. Alphabet, the parent, \"continued its significant investment\". Returning investors named: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The page refers to \"several other new investors\" without naming them. The money is for scaling the company's drug design engine, IsoDDE, and its pipeline of AI-designed therapeutic candidates. The page states no valuation, no headcount, no partnership names, no allocation of the funds, no named candidate, no indication and no clinical stage, and it carries no attributed quotation. The company was founded in 2021 out of Google DeepMind and is based in London. Secondary reporting, marked as reported: the Series B of about $2.1 billion was announced in May 2026; BioPharma Dive calls the 2 rounds the largest venture infusions of the year among the 26 AI drug firms it tracks, and this the largest financing it has recorded since 2022; named partners are Novartis, Johnson & Johnson and Lilly; the company reports positive preclinical results in oncology and immunology \"setting the stage for clinical entry\"; and no AI-designed medicine has been approved anywhere. Isomorphic says its technology can \"deliver exquisitely engineered molecules with optimal drug-like properties\", a company claim with no published trial behind it. Not established: the valuation, Alphabet's share, the identity of the remaining new investors, whether any candidate has entered or been cleared for human trials, and what fraction of the $5 billion is primary capital rather than secondary purchases of existing shares.","update":"$7.1 billion arrived first, from crossover funds and sovereign money."},"inference":{"established":["$5 billion Series C, led by Greenoaks and Sequoia Capital, announced November 17.","Andreessen Horowitz is new; Thrive, MGX, GV, CapitalG and Temasek returned.","The announcement names no pipeline candidate, indication or clinical stage."],"unknown":["The valuation. Isomorphic did not disclose it.","That anything is in the clinic. No trial is named.","What Alphabet put in, or who the other new investors are."]},"narrative":{"hook":"Isomorphic Labs raised $5 billion, 6 months after raising $2.1 billion.","plain":"Isomorphic announced the Series C on November 17, led by Greenoaks and Sequoia Capital, with Alphabet continuing to invest. No valuation was disclosed.","story":["Greenoaks and Sequoia lead, Andreessen Horowitz is new, and Temasek, MGX and the UK Sovereign AI Fund are already in. That is generalist and state capital pricing a discovery engine, not pharma buying a pipeline. The company names no candidate, no indication and no trial."],"trail":[{"d":"MAY 2026","t":"Isomorphic announces a Series B of about $2.1 billion, reported as the largest round of the year in AI drug discovery at that point."},{"d":"SEP 8","t":"Edition 015 cards the thinnest lane in this ledger, science, for the first time; Editions 045 and 053 are the only others before this month."},{"d":"NOV 13","t":"Google's agents machine-check proofs of 6 hard problems and the tool opens to 10,000 users. Edition 094."},{"d":"NOV 16","t":"NVIDIA publishes Nemotron for Science with weights, a 50,000-question chemistry dataset, and Argonne, Julich, KTH and RIKEN already building on it. Edition 098."},{"d":"NOV 17","t":"Isomorphic announces the $5 billion Series C, with Greenoaks and Sequoia leading and Andreessen Horowitz new. No valuation, no candidate, no trial named."},{"d":"Reacts","r":true,"t":"Novartis, Johnson & Johnson and Lilly, whose partnerships now sit beside $7.1 billion of outside capital; Alphabet, diluted in its own spinout; Recursion, Insilico and every AI drug firm that must now raise against this mark; the regulators who will see the first filing; and the sovereign funds of Abu Dhabi, Singapore and Britain, now co-investors in the same engine."}],"glossary":[{"term":"Series C","def":"A third round of venture funding. At this size it usually mixes new money into the company with purchases of shares from earlier investors."},{"term":"Preclinical","def":"Work done before a drug is given to people, in cells and animals. Most compounds that look good here fail once humans are dosed."},{"term":"Crossover fund","def":"An investor that buys both private and public shares. Their arrival usually signals they expect a listing or a large sale within a few years."},{"term":"Sovereign wealth fund","def":"A state-owned investment fund. MGX is Abu Dhabi's AI vehicle; Temasek is Singapore's; the UK fund is British government money."}]},"judgment":{"prompt":"Which explanation do you believe?","interpretations":[{"id":"a","label":"Capital is pricing the engine","text":"Investors are buying a design platform, not a pipeline, and will wait for trials.","abstain":false},{"id":"b","label":"A clinical filing is close","text":"Preclinical results in oncology and immunology, and money raised to run trials.","abstain":false},{"id":"c","label":"An Alphabet asset being set up","text":"Crossover funds and sovereign money arriving together is how a listing gets built.","abstain":false},{"id":"d","label":"The normal AI funding cycle","text":"Every AI lane is raising at these sizes. Drug design is simply the latest.","abstain":false},{"id":"e","label":"Too early to call.","text":"The evidence cannot yet separate these.","abstain":true}],"distribution":{"status":"held back until you have made your call","calls":null}},"story_thread":null,"what_to_watch":[{"linked_interpretation":"c","direction":"strengthens","observable_event":"Isomorphic or Alphabet files for a listing, confidentially or publicly, or discloses a secondary component or a valuation above $50 billion, by December 31, 2027.","window_end":"2027-12-31","state":"unresolved"},{"linked_interpretation":"b","direction":"strengthens","observable_event":"Isomorphic names a candidate entering human trials, or a trial registration naming Isomorphic appears on a public registry, by December 31, 2027.","window_end":"2027-12-31","state":"unresolved"},{"linked_interpretation":"a","direction":"weakens","observable_event":"Isomorphic discloses no candidate in human trials by December 31, 2027, or a named partner among Novartis, Johnson & Johnson and Lilly ends its collaboration.","window_end":"2027-12-31","state":"unresolved"}]}